At the end of January, the small-cap biotechnology company AVEO Oncology (AVEO) updated investors on the delayed timeline for filing with FDA for their lead compound tivozanib. This news led to a … [Read more...] about Evaluating the Merits of AVEO’s Potential Purchase
Bristol-Myers Squibb
Acquisition Targets: Could Bluebird Be In Season?
Acquisitions in pharmaceutical industry staying at an elevated paceStrong balance sheet even before having any drugs approved for salePromising lentiviral genetic treatment platformSignificant … [Read more...] about Acquisition Targets: Could Bluebird Be In Season?
Bristol-Myers Squibb Positioned For Deep Penetration In the Multiple Myeloma Market
Introduction Bristol-Myers Squibb (NYSE: BMY) is a profitable global bio-pharmaceutical company targeting an array of serious diseases and unmet medical needs. Earlier this month BMY announced … [Read more...] about Bristol-Myers Squibb Positioned For Deep Penetration In the Multiple Myeloma Market
MS Monday Update-ADMA, CELG
LEAVE A COMMENT AND CLICK HERE TO SUBSCRIBE FOR MS ARTICLE ALERTS AND OUR NEWSLETTER! Adma Biologics (Nasdaq: ADMA) announced today filing of supplementary information to the FDA in … [Read more...] about MS Monday Update-ADMA, CELG
GALT is Primed for Acquisition or Partnership
Overview Galectin Therapeutics (NASDAQ GALT $5.96) is a leader in the development of a treatment for Non-Alcoholic SteatoHepatitis, an unmet medical need worth billions. Their star drug … [Read more...] about GALT is Primed for Acquisition or Partnership
English
Arabic
Chinese (Simplified)
Dutch
French
German
Italian
Japanese
Portuguese
Russian
Spanish
You must be logged in to post a comment.